Non-Hodgkin Lymphoma | Specialty

Q4 2025: 10 FDA Decisions to Watch in the Realm of Oncology

October 3rd 2025

Here is your Q4 2025 preview spotlighting 10 FDA decisions to watch, including upcoming PDUFAs for belantamab mafodotin, revumenib, sevabertinib, and more.

OncLive Poll Results Spotlight Highly Anticipated Hematology Topics Ahead of ESMO 2025

October 3rd 2025

Multiple myeloma and non-Hodgkin lymphoma emerge as key hematology topics ahead of ESMO 2025, followed by MPNs and T-cell lymphoma.

Dr Dahiya on the Unique Mechanism of Action of KITE-363 in LBCL

October 1st 2025

Saurabh Dahiya, MD, FACP, discusses the unique mechanism of action of the CD19/CD20–targeting CAR T-cell therapy in relapsed/refractory LBCL.

Dr Vose on Common Adverse Effects With Epcoritamab in Relapsed/Refractory LBCL

September 30th 2025

Julie M. Vose, MD, MBA, discusses the safety profile of epcoritamab in patients with relapsed/refractory LBCL who have achieved a 2-year complete response.

Hematologic Oncology Abstracts to Watch at the 2025 ESMO Congress

September 30th 2025

A preview of the hematologic oncology abstracts and presentations to watch at the 2025 ESMO Congress in Berlin.

Poll: Vote on the Top Breast Cancer, Hematology Abstracts to Watch at ESMO 2025

September 29th 2025

KITE-363 Shows Potential As a Next-Generation CAR T-Cell Therapy for R/R LBCL

September 26th 2025

Saurabh Dahiya, MD, FACP, discussed how the unique mechanism of action of KITE-363 may improve upon the efficacy of other CAR T-cell therapies for LBCL.

CHMP Recommends EU Approval of Subcutaneous Mosunetuzumab in R/R Follicular Lymphoma

September 19th 2025

The CHMP has recommended the European approval of subcutaneous mosunetuzumab in relapsed/refractory follicular lymphoma.

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma

September 11th 2025

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Mosunetuzumab Plus Polatuzumab Vedotin Triples Median PFS in Transplant-Ineligible LBCL

September 6th 2025

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

Off-the-Shelf, Fixed-Duration Combination Is Active in Relapsed/Refractory MCL

September 6th 2025

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

Loncastuximab Tesirine Plus Glofitamab Shows Early Safety and Efficacy in R/R DLBCL

September 6th 2025

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

OncLive’s August Roundup of Key FDA Approvals in Oncology: 3 Decisions to Know

September 2nd 2025

Here is your guide to all therapeutic options that were cleared by the FDA in August 2025 spanning tumor types.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Health Canada Approves Glofitamab Plus Chemotherapy for R/R DLBCL

August 22nd 2025

Glofitamab plus GemOx received approval in Canada for patients with relapsed or refractory DLBCL not otherwise specified who are not eligible for ASCT.

European Commission Approves Zanubrutinib Tablet Formulation for All Indications in B-Cell Malignancies

August 21st 2025

The European approval of a zanubrutinb tablet formulation covers indications in CLL, Waldenström macroglobulinemia, MZL, and follicular lymphoma.

Five Under 5: Top Oncology Videos for the Week of 8/10

August 17th 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Real-World Data Highlight Feasibility of CAR T-Cell Therapy in Patients With Aggressive Lymphomas and Active Autoimmune Disease

August 14th 2025

Retrospective data showed CAR T-cell therapy is feasible in patients with aggressive lymphomas and active autoimmune diseases.

CD19 t-haNK Leads to Complete Responses in Waldenstrom Macroglobulinemia

August 13th 2025

CD19 t-haNK demonstrated complete responses in 2 patients with heavily pretreated Waldenstrom macroglobulinemia.

The OncFive: Top Oncology Articles for the Week of 8/3

August 9th 2025

The FDA grants accelerated approval to zongertinib in lung cancer, clears dordaviprone in glioma, and awards priority review to liso-cel sBLA in MZL.